The BioWorld Insider Podcast

Karen Carey, BioWorld 's managing editor and senior data analyst, and Tim Shannon, a general partner at Canaan, break down the numbers from first quarter of 2023. Hosted on Acast. See acast.com/privacy for more information.

BioWorld Staff Writer Tamra Sami talks about the science behind radiopharmaceuticals, the supply chain vulnerabilities, the regulatory landscape, the patient journey and therapies in the pipeline. Hosted on Acast. See acast.com/privacy for more information.

James Peyer, the CEO of Cambrian Biopharma Inc., talks about anti-aging therapies, a business model that fits the new field of geroscience. Hosted on Acast. See acast.com/privacy for more information.

BioWorld Science Managing Editor Anette Breindl discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness that in many ways go against mainstream theories about obesity. Hosted on Acast. See acast.com/privacy for more information.

Guests Karen Zaderej, CEO of Axogen Inc., Sean Bohen, CEO of Olema Oncology Inc., Rob Ross, the CEO of Surface Oncology Inc., and Rob Etherington, the CEO of Clene Nanomedicine Inc., speak about adapting their companies to the market's new realities.   Hosted on Acast. See acast.com/privacy for more information.

James Lanthier, the CEO of Mindset Pharma Inc., talks about developing next-generation psychedelic medicines to treat neurological and psychiatric disorders. Hosted on Acast. See acast.com/privacy for more information.

BioWorld Senior Analyst Karen Carey chats about the collision of a volatile economic climate and big biopharma deals. Hosted on Acast. See acast.com/privacy for more information.

Extending the human lifespan , a  BioWorld special report, examines the companies developing "Fountain of Youth" drugs. In this episode, the writers discuss this scientific holy grail. Hosted on Acast. See acast.com/privacy for more information.

Executives from Amylyx Pharmaceuticals Inc. and Clene Inc., along with a key Penn State ALS expert, discuss what the future of medicine holds for patients. Hosted on Acast. See acast.com/privacy for more information.

BioWorld Senior Analyst Karen Carey explores the newest data and where it is leading. Hosted on Acast. See acast.com/privacy for more information.

Infection control expert William Schaffner of the Vanderbilt University School of Medicine joins to discuss the CDC's Advisory Committee on Immunization Practices and how COVID-19 put the committee's schedule into overdrive.

Senior Science Editor Anette Breindl goes in depth about how long COVID-19 emerged and is being defined. Hosted on Acast. See acast.com/privacy for more information.

Guests Ryan Abbott, a professor of law and medicine, as well as the leader of the Artificial Inventor Project, and Jim Belfiore, senior vice president of innovation at Clarivate plc, have a discussion about the brave new world AI is creating. Hosted on Acast. See acast.com/privacy for more information.

A conversation with Kleanthis Xanthopoulos, a co-founder and executive chairman of Shoreline Biosciences, and Joe Hernandez, CEO and executive chairman of Blue Water Vaccines, who have founded or led eight health care and pharmaceuticals companies. Hosted on Acast. See acast.com/privacy for more information.

Insights into the controversial drug come from guests Michael Agadjanyan, president of Nuravax Inc., which is developing antibodies for preventing Alzheimer's and Parkinson's diseases, along with Robert Glanzman, chief medical officer of Clene Nanomedicine Inc. Hosted on Acast. See acast.com/privacy for more information.

Paul Testa, executive vice president for operations and supply chain at Tokyo-based Kyowa Kirin, on the dramatic importance of continuity, reliability of supply, business process and automation. Hosted on Acast. See acast.com/privacy for more information.

Peter Pitts, president of the Center for Medicine in the Public Interest, on how government regulation seems like a slow but in actuality moves more quickly than understood. Hosted on Acast. See acast.com/privacy for more information.

BioWorld Regulatory Editor Mari Serebrov puts the pandemic and the science into perspective. Hosted on Acast. See acast.com/privacy for more information.

Joseph Allen, executive director of the Bayh-Dole Coalition, explains how molnupiravir, from Ridgeback Biotherapeutics, and partner Merck & Co. Inc., may have never had a chance to move out of the university onto pharmacy shelves without the government's support.   Hosted on Acast. See acast.com/privacy for more information.

The approval of antibody-drug conjugate Tivdak (tisotumab vedotin) for treating cervical cancer and the future of Genmab A/S are the subjects with the company's president and CEO, Jan van de Winkel. Hosted on Acast. See acast.com/privacy for more information.

An in-depth conversation with Lucio Rovati, CEO and chief scientific officer of Italy's Rottapharm Biotech as they tackle the new world of DNA vaccines.   Hosted on Acast. See acast.com/privacy for more information.

Laurie Halloran, president and CEO of Boston-based Halloran Consulting, shares her thoughts on the impact of COVID-19 on clinical trials.

Mark Goldsmith, Revolution Medicines Inc. president, CEO and chairman, talks about grappling with RAS mutations. Hosted on Acast. See acast.com/privacy for more information.

Howard Fillit, founding executive director and chief science officer at the Alzheimer's Drug Discovery Foundation, shares his insights on the impact of financial investments driving these therapies.

Biopharma deal-making activity, a closely watched marker of industry health, was alive and well in the second quarter. BioWorld Senior Analyst Karen Carey sifts through the numbers.   Hosted on Acast. See acast.com/privacy for more information.